The world's largest producer of electricity from the wind and sun is surprisingly optimistic about the future of renewable energy.
Trade investigations and a stumbling patent portfolio have investors growing anxious about the pending acquisition by Illumina.
The world's a pretty big place. Expand your portfolio's horizons with these international businesses.
Investors will be focused on a potentially trajectory-altering product launch, but it will be several quarters (at least) before we can start drawing conclusions about its impact.
The company pulled the trigger on a massive public stock offering. And why not?
The business announced a private placement to pad its balance sheet ahead of a major expansion.
The public markets are awash in new biopharmaceutical companies, but these two appear to be overlooked.
Gene therapy developers might steal all of the headlines, but manufacturing is likely to be the more lucrative investing opportunity -- for both companies and investors.
The gene therapy developer announced higher-than-expected demand for its public stock offering.
The copper and gold miner reported solid second-quarter 2019 production results, but announced mounting challenges at an important growth asset.
Investors are excited about two new products for the genetic testing and liquid biopsy developer.
The company put a clinical hold from 2018 behind it and submitted its first-ever new drug application.
The marijuana craze has hit this clinical-stage pharmaceutical company.
Investors are excited (perhaps a little too excited) about a new opportunity in immuno-oncology.
The genetic testing leader continues to set new quarterly revenue records.
Gene therapies, here we come.
China's biopharma gem drifted lower in the first half of 2019, but there's no identifiable explanation or cause for concern.
Wall Street admitted that it may have overreacted last year.
Investors were all too happy to reward the business for its hasty progress on an operating efficiency program.
The bioprocess engineering leader continued to deliver spectacular growth and bolster its profitability.